Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats

Neuroscience

Volumn 256, Issue , 2014, Pages 210-222

  Zheng, X ^a,b   Liang, Y ^a   Kang, A ^a,c   Ma, S J ^a   Xing, L ^a   Zhou, Y Y ^a   Dai, C ^a   Xie, H ^a   Xie, L ^a   Wang, G J ^a   Hao, H P ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

CNS drug discovery; Depression; Ginsenoside Rg1; Microglia; Neuroinflammation; Peripheral target

Indexed keywords

GINSENOSIDE RG 1; IMMUNOMODULATING AGENT; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; CENTRAL NERVOUS SYSTEM AGENTS; CYTOKINE; GINSENOSIDE; MINOCYCLINE; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANOREXIA; ARTICLE; BEHAVIOR DISORDER; CELL ACTIVATION; CONTROLLED STUDY; DEPRESSION; DEREGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MENTAL DISEASE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EATING; ENCEPHALITIS; FOOD PREFERENCE; GENETICS; IMMUNOLOGY; MALE; MENTAL DISORDERS; METABOLISM; TOXICITY; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; CENTRAL NERVOUS SYSTEM AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENCEPHALITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOOD PREFERENCES; GINSENOSIDES; LIPOPOLYSACCHARIDES; MALE; MENTAL DISORDERS; MINOCYCLINE; RATS; RATS, WISTAR; SEROTONIN;

EID: 84888089377     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.10.023     Document Type: Article

References (74)

1. Aden U., Favrais G., Plaisant F., Winerdal M., Felderhoff-Mueser U., Lampa J., Lelievre V., Gressens P. Systemic inflammation sensitizes the neonatal brain to excitotoxicity through a pro-/anti-inflammatory imbalance: key role of TNFalpha pathway and protection by etanercept. Brain Behav Immun 2010, 24:747-758.
2. Aid S., Silva A.C., Candelario-Jalil E., Choi S.H., Rosenberg G.A., Bosetti F. Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity. J Cereb Blood Flow Metab 2010, 30:370-380.
3. Beynon S.B., Walker F.R. Microglial activation in the injured and healthy brain: what are we really talking about? Practical and theoretical issues associated with the measurement of changes in microglial morphology. Neuroscience 2012, 225:162-171.
4. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
5. Breckwoldt M.O., Chen J.W., Stangenberg L., Aikawa E., Rodriguez E., Qiu S., Moskowitz M.A., Weissleder R. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci USA 2008, 105:18584-18589.
6. Campbell S.J., Hughes P.M., Iredale J.P., Wilcockson D.C., Waters S., Docagne F., Perry V.H., Anthony D.C. CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury. FASEB J 2003, 17:1168-1170.
7. Campbell S.J., Jiang Y., Davis A.E., Farrands R., Holbrook J., Leppert D., Anthony D.C. Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute-phase response. J Neurochem 2007, 103:2245-2255.
8. Cecchelli R., Berezowski V., Lundquist S., Culot M., Renftel M., Dehouck M.P., Fenart L. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007, 6:650-661.
9. Chapman K.Z., Dale V.Q., Denes A., Bennett G., Rothwell N.J., Allan S.M., McColl B.W. A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke. J Cereb Blood Flow Metab 2009, 29:1764-1768.
10. Choi S.H., Langenbach R., Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J 2008, 22:1491-1501.
11. Clapper J.R., Moreno-Sanz G., Russo R., Guijarro A., Vacondio F., Duranti A., Tontini A., Sanchini S., Sciolino N.R., Spradley J.M., Hohmann A.G., Calignano A., Mor M., Tarzia G., Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 2010, 13:1265-1270.
12. Cohen L.J., Sclar D.A. MAOIs: issues in treatment adherence and rates of treatment failure. J Clin Psychiatry 2013, 74:e02.
13. Connor T.J., Starr N., O'Sullivan J.B., Harkin A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?. Neurosci Lett 2008, 441:29-34.
14. Cryan J.F., Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 2004, 9:326-357.
15. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
16. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
17. De Simoni M.G., Terreni L., Chiesa R., Mangiarotti F., Forloni G.L. Interferon-gamma potentiates interleukin (IL)-6 and tumor necrosis factor-alpha but not IL-1beta induced by endotoxin in the brain. Endocrinology 1997, 138:5220-5226.
18. Dobos N., de Vries E.F., Kema I.P., Patas K., Prins M., Nijholt I.M., Dierckx R.A., Korf J., den Boer J.A., Luiten P.G., Eisel U.L. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis 2012, 28:905-915.
19. Du J., Cheng B., Zhu X., Ling C. Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects. J Immunol 2011, 187:942-950.
20. Farooq R.K., Isingrini E., Tanti A., Le Guisquet A.M., Arlicot N., Minier F., Leman S., Chalon S., Belzung C., Camus V. Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation?. Behav Brain Res 2012, 231:130-137.
21. Feng L., Wang L., Hu C., Jiang X. Pharmacokinetics, tissue distribution, metabolism, and excretion of ginsenoside Rg1 in rats. Arch Pharm Res 2010, 33:1975-1984.
22. Garrido-Mesa N., Zarzuelo A., Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013, 169:337-352.
23. Gidday J.M., Gasche Y.G., Copin J.C., Shah A.R., Perez R.S., Shapiro S.D., Chan P.H., Park T.S. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005, 289:H558-H568.
24. Gleeson M.P., Hersey A., Montanari D., Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 2011, 10:197-208.
25. Gosselin D., Rivest S. MyD88 signaling in brain endothelial cells is essential for the neuronal activity and glucocorticoid release during systemic inflammation. Mol Psychiatry 2008, 13:480-497.
26. Haider S., Saleem S., Tabassum S., Khaliq S., Shamim S., Batool Z., Parveen T., Inam Q.U., Haleem D.J. Alteration in plasma corticosterone levels following long term oral administration of lead produces depression like symptoms in rats. Metab Brain Dis 2013, 28:85-92.
27. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
28. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., Sheridan J.F., Godbout J.P. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflamm 2008, 5:15.
29. Huang Y., Henry C.J., Dantzer R., Johnson R.W., Godbout J.P. Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. Neurobiol Aging 2008, 29:1744-1753.
30. Iniguez S.D., Warren B.L., Parise E.M., Alcantara L.F., Schuh B., Maffeo M.L., Manojlovic Z., Bolanos-Guzman C.A. Nicotine exposure during adolescence induces a depression-like state in adulthood. Neuropsychopharmacology 2009, 34:1609-1624.
31. Ito D., Tanaka K., Suzuki S., Dembo T., Fukuuchi Y. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 2001, 32:1208-1215.
32. Jiang Y., Deacon R., Anthony D.C., Campbell S.J. Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases. Neurobiol Dis 2008, 32:125-132.
33. Joo S.S., Won T.J., Lee D.I. Reciprocal activity of ginsenosides in the production of proinflammatory repertoire, and their potential roles in neuroprotection in vivo. Planta Med 2005, 71:476-481.
34. Kalehua A.N., Taub D.D., Baskar P.V., Hengemihle J., Munoz J., Trambadia M., Speer D.L., De Simoni M.G., Ingram D.K. Aged mice exhibit greater mortality concomitant to increased brain and plasma TNF-alpha levels following intracerebroventricular injection of lipopolysaccharide. Gerontology 2000, 46:115-128.
35. Kang A., Hao H., Zheng X., Liang Y., Xie Y., Xie T., Dai C., Zhao Q., Wu X., Xie L., Wang G. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J Neuroinflam 2011, 8:100.
36. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
37. Kim Y.S., Kim S.S., Cho J.J., Choi D.H., Hwang O., Shin D.H., Chun H.S., Beal M.F., Joh T.H. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci 2005, 25:3701-3711.
38. Klumpers L.E., Fridberg M., de Kam M.L., Little P.B., Jensen N.O., Kleinloog H.D., Elling C.E., van Gerven J.M. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol 2013, [Epub ahead of print]. 10.1111/bcp.12141.
39. Kumar R., Anstey K.J., Cherbuin N., Wen W., Sachdev P.S. Association of type 2 diabetes with depression, brain atrophy, and reduced fine motor speed in a 60- to 64-year-old community sample. Am J Geriatr Psychiatry 2008, 16:989-998.
40. Kumar S., Selim M.H., Caplan L.R. Medical complications after stroke. Lancet Neurol 2010, 9:105-118.
41. Lawson M.A., Kelley K.W., Dantzer R. Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav Immun 2011, 25:1569-1575.
42. Lawson M.A., McCusker R.H., Kelley K.W. Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice. J Neuroinflamm 2013, 10:54.
43. Li X., Wang G., Sun J., Hao H., Xiong Y., Yan B., Zheng Y., Sheng L. Pharmacokinetic and absolute bioavailability study of total panax notoginsenoside, a typical multiple constituent traditional Chinese medicine (TCM) in rats. Biol Pharm Bull 2007, 30:847-851.
44. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
45. Loftis J.M., Huckans M., Morasco B.J. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 2010, 37:519-533.
46. Lu D.Y., Tsao Y.Y., Leung Y.M., Su K.P. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology 2010, 35:2238-2248.
47. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24:27-53.
48. Marchi N., Fan Q., Ghosh C., Fazio V., Bertolini F., Betto G., Batra A., Carlton E., Najm I., Granata T., Janigro D. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis 2009, 33:171-181.
49. Mika J., Osikowicz M., Makuch W., Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007, 560:142-149.
50. Miller A.H. Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 2009, 23:149-158.
51. Neuwelt E., Abbott N.J., Abrey L., Banks W.A., Blakley B., Davis T., Engelhardt B., Grammas P., Nedergaard M., Nutt J., Pardridge W., Rosenberg G.A., Smith Q., Drewes L.R. Strategies to advance translational research into brain barriers. Lancet Neurol 2008, 7:84-96.
52. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14:511-522.
53. Pangalos M.N., Schechter L.E., Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007, 6:521-532.
54. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008, 31:464-468.
55. Park S.E., Dantzer R., Kelley K.W., McCusker R.H. Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J Neuroinflamm 2011, 8:12.
56. Patel M.M., Goyal B.R., Bhadada S.V., Bhatt J.S., Amin A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009, 23:35-58.
57. Plane J.M., Shen Y., Pleasure D.E., Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010, 67:1442-1448.
58. Raedler T.J. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011, 24:519-525.
59. Rapoport M.J. Depression following traumatic brain injury: epidemiology, risk factors and management. CNS Drugs 2012, 26:111-121.
60. Steiner O., Coisne C., Cecchelli R., Boscacci R., Deutsch U., Engelhardt B., Lyck R. Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-resistant T cell arrest, polarization, and directed crawling on blood-brain barrier endothelium. J Immunol 2010, 185:4846-4855.
61. Steinman L. Modulation of postoperative cognitive decline via blockade of inflammatory cytokines outside the brain. Proc Natl Acad Sci USA 2010, 107:20595-20596.
62. Taylor L.C., Puranam K., Gilmore W., Ting J.P., Matsushima G.K. 17beta-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss. Neurobiol Dis 2010, 39:127-137.
63. Terrando N., Monaco C., Ma D., Foxwell B.M., Feldmann M., Maze M. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci USA 2010, 107:20518-20522.
64. Tonelli L.H., Holmes A., Postolache T.T. Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology 2008, 33:1038-1048.
65. Tynan R.J., Weidenhofer J., Hinwood M., Cairns M.J., Day T.A., Walker F.R. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012, 26:469-479.
66. Wong M.L., Dong C., Maestre-Mesa J., Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008, 13:800-812.
67. Woo M.S., Park J.S., Choi I.Y., Kim W.K., Kim H.S. Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem 2008, 106:770-780.
68. Xu L., Chen W.F., Wong M.S. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. Br J Pharmacol 2009, 158:738-748.
69. Yang L., Froio R.M., Sciuto T.E., Dvorak A.M., Alon R., Luscinskas F.W. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 2005, 106:584-592.
70. Zheng X., Kang A., Dai C., Liang Y., Xie T., Xie L., Peng Y., Wang G., Hao H. Quantitative analysis of neurochemical panel in rat brain and plasma by liquid chromatography-tandem mass spectrometry. Anal Chem 2012, 84:10044-10051.
71. Zhou H., Lapointe B.M., Clark S.R., Zbytnuik L., Kubes P. A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J Immunol 2006, 177:8103-8110.
72. Zong Y., Ai Q.L., Zhong L.M., Dai J.N., Yang P., He Y., Sun J., Ling E.A., Lu D. Ginsenoside Rg1 attenuates lipopolysaccharide-induced inflammatory responses via the phospholipase C-gamma1 signaling pathway in murine BV-2 microglial cells. Curr Med Chem 2012, 19:770-779.
73. Zunszain P.A., Anacker C., Cattaneo A., Choudhury S., Musaelyan K., Myint A.M., Thuret S., Price J., Pariante C.M. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012, 37:939-949.
74. Zwilling D., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Guidetti P., Wu H.Q., Lee J., Truong J., Andrews-Zwilling Y., Hsieh E.W., Louie J.Y., Wu T., Scearce-Levie K., Patrick C., Adame A., Giorgini F., Moussaoui S., Laue G., Rassoulpour A., Flik G., Huang Y., Muchowski J.M., Masliah E., Schwarcz R., Muchowski P.J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.